arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

MACROGENICS INC

MGNX
$2.23 ▼ -0.08 (-3.66%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

MACROGENICS INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $140.8M
Dividend Yield —
Revenue Growth -0.3% ↘
Op. Margin -48.7% ↗
ROIC -129.9% ↘
FCF / Share $-1.31 ↘
Trailing P/E —
Price / Book 2.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$149.50M
— -0.3% —
Net Income Profit after all expenses
$-74.62M
↓ -11.4% —
Operating Margin Operating profit as % of sales
-48.7%
↑ +33.9% 5th
FCF / Share Free cash flow per share
$-1.31
↓ -14.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
5
Returns ↓
6
Cash Quality ↑
70

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 16 years · 58 quarters